피부과 치료제 시장(2024-2034년)

The global Dermatological Drugs Market is projected to grow at a CAGR 10.5% by 2034

The Dermatological Drugs Market Report 2024-2034: This report is essential for prominent enterprises seeking fresh revenue opportunities, aiming to enhance their comprehension of the industry and its inherent dynamics. It provides valuable insights for firms interested in diversifying across various sectors or expanding their current activities into new geographical areas.

Geriatric Population Driving Demand for Dermatological Drugs

As the global population ages at an unprecedented pace, the dermatological drugs market is poised for a significant upswing. According to the World Health Organization (WHO), by 2050, 80% of older individuals will reside in low- and middle-income countries. The rapid acceleration in population aging, outpacing historical trends, is a key catalyst. As per WHO, by 2030, one in every 6 person will be aged 60 or over. Also, from 2021 to 2050, population aged over 65 in Asia will grow by more than half-a-billion, creating a burgeoning market for dermatological drugs. This demographic shift signifies an increased demand for skincare solutions tailored to age-related dermatological concerns, such as wrinkles, age spots, and skin conditions prevalent in the elderly. Thus, the coming years will mark a lucrative era for the dermatological drugs industry, driven by the unique needs of the expanding geriatric population.

Nanotechnology in Drug Delivery Could Revolutionize the Dermatological Drugs Market

In the dynamic landscape of dermatology, the integration of cutting-edge technological advancements in drug delivery is poised to propel the market to unprecedented heights. The advent of nanotechnology enables precise targeting of skin cells, enhancing the efficacy of dermatological drugs while minimizing side effects. This revolutionary approach ensures a more tailored and efficient treatment, boosting patient outcomes and satisfaction. Micro-needle technology is reshaping the administration of dermatological drugs. These minimally invasive devices painlessly penetrate the skin, facilitating controlled and sustained release of therapeutic agents. This not only improves patient compliance but also optimizes drug absorption, leading to quicker and more effective results. Several companies are actively researching and developing nanocarriers and smart delivery systems for skincare applications such as NanoVibronix (US) and Nanologica (Sweden).

Furthermore, the incorporation of smart polymers in drug formulations represents a paradigm shift in dermatological treatments. These polymers respond to specific physiological cues, releasing drugs at the right time and in the right amounts. This precision enhances therapeutic outcomes, reduces the frequency of application, and minimizes adverse reactions.

What Questions Should You Ask before Buying a Market Research Report?

How is the Dermatological Drugs market evolving?

What is driving and restraining the Dermatological Drugs market?

How will each Dermatological Drugs submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2034?

How will the market shares for each Dermatological Drugs submarket develop from 2024 to 2034?

What will be the main driver for the overall market from 2024 to 2034?

Will leading Dermatological Drugs markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?

How will the market shares of the national markets change by 2034 and which geographical region will lead the market in 2034?

Who are the leading players and what are their prospects over the forecast period?

What are the Dermatological Drugs projects for these leading companies?

How will the industry evolve during the period between 2024 and 2034? What are the implications of Dermatological

Drugs projects taking place now and over the next 10 years?

Is there a greater need for product commercialisation to further scale the Dermatological Drugs market?

Where is the Dermatological Drugs market heading and how can you ensure you are at the forefront of the market?

What are the best investment options for new product and service lines?

What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the Dermatological Drugs market today, and over the next 10 years:

Our 280-page report provides 113 tables and 160 charts/graphs exclusively to you.

The report highlights key lucrative areas in the industry so you can target them - NOW.

It contains in-depth analysis of global, regional and national sales and growth.

It highlights for you the key successful trends, changes and revenue projections made by your competitors.

This report tells you TODAY how the Dermatological Drugs market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.

Forecasts to 2034 and other analyses reveal commercial prospects

In addition to revenue forecasting to 2034, our new study provides you with recent results, growth rates, and market shares.

You will find original analyses, with business outlooks and developments.

Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising Dermatological Drugs prices and recent developments.

This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, "V", "L", "W" and "U" are discussed in this report.

Segments Covered in the Report

Route of Administration

Topical

Oral

Parenteral Administration

Disease

Psoriasis

Dermatitis

Acne

Skin Infections

Others

Prescription Mode

Prescription Drugs

Over-the-Counter (OTC) Drugs

Distribution Channel

Retail Pharmacies

Hospital Pharmacies

Online Pharmacies

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 21 leading national markets:

North America

U.S.

Canada

Europe

Germany

UK

France

Spain

Italy

Russia

Rest of Europe

Asia Pacific

China

Japan

India

Australia

South Korea

Rest of Asia Pacific

Latin America

Brazil

Mexico

Rest of Latin America

MEA

GCC

South Africa

Rest of MEA

The report also includes profiles and for some of the leading companies in the Dermatological Drugs Market, 2024 to 2034, with a focus on this segment of these companies' operations.

Leading companies profiled in the report

AbbVie Inc.

AstraZeneca

Bayer AG

DermBiont, Inc.

F. Hoffmann-La Roche Ltd

GSK plc

Johnson & Johnson Services, Inc.

LEO Pharma A/S

Mayne Pharma Group Limited

Merck & Co., Inc.

Novartis AG

Pfizer Inc.

Regeneron Pharmaceuticals Inc.

Roivant Sciences Ltd.

Teva Pharmaceutical Industries Ltd.

Verrica Pharmaceuticals

Overall world revenue for Dermatological Drugs Market, 2024 to 2034 in terms of value the market will surpass US$30.0 billion in 2024, our work calculates. We predict strong revenue growth through to 2034. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How will the Dermatological Drugs Market, 2024 to 2034 report help you?

In summary, our 280-page report provides you with the following knowledge:

Revenue forecasts to 2034 for Dermatological Drugs Market 2024 to 2034, with forecasts for route of administration, disease, prescription mode, and distribution channel each forecast at a global and regional level - discover the industry's prospects, finding the most lucrative places for investments and revenues.

Revenue forecasts to 2034 for five regional and 21 key national markets - See forecasts for the Dermatological Drugs Market, 2024 to 2034 market in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.

Prospects for established firms and those seeking to enter the market - including company profiles for 16 of the major companies involved in the Dermatological Drugs Market, 2024 to 2034.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.

Information found nowhere else

With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain's study is for everybody needing commercial analyses for the Dermatological Drugs Market, 2024 to 2034, market-leading companies. You will find data, trends and predictions.

Table of Contents

1 Report Overview

• 1.1 Objectives of the Study
• 1.2 Introduction to Dermatological Drugs Market
• 1.3 What This Report Delivers
• 1.4 Why You Should Read This Report
• 1.5 Key Questions Answered by This Analytical Report
• 1.6 Who is This Report for?
• 1.7 Methodology
  • 1.7.1 Market Definitions
  • 1.7.2 Market Evaluation & Forecasting Methodology
  • 1.7.3 Data Validation
    • 1.7.3.1 Primary Research
    • 1.7.3.2 Secondary Research
• 1.8 Frequently Asked Questions (FAQs)
• 1.9 Associated Visiongain Reports
• 1.10 About Visiongain

2 Executive Summary

3 Market Overview

• 3.1 Key Findings
• 3.2 Market Dynamics
  • 3.2.1 Market Driving Factors
    • 3.2.1.1 Increasing Prevalence of Skin Disorders
    • 3.2.1.2 Growing Awareness and Patient Education
    • 3.2.1.3 Globalization and Urbanization
    • 3.2.1.4 Revolutionizing Dermatology: Unleashing Market Growth Through Advanced Drug Delivery Technologies
    • 3.2.1.5 Innovative Breakthroughs: Propelling Dermatological Drugs Market Through Surging R&D Investments
    • 3.2.1.6 Geriatric Population Driving Dermatological Drugs Market
  • 3.2.2 Market Restraining Factors
    • 3.2.2.1 Generic Competition
    • 3.2.2.2 Adverse Effects and Safety Concerns
    • 3.2.2.3 Drug Resistance
    • 3.2.2.4 Non-Pharmacological Options: A Hindrance to Dermatological Drugs Market Growth
    • 3.2.2.5 Limited Reimbursement and Coverage Challenges in Dermatological Drugs Sector
    • 3.2.2.6 Regulatory Approval Process Poses Barriers to Dermatological Drugs Market Growth
  • 3.2.3 Market Opportunities
    • 3.2.3.1 Approval of Novel Dermatological Drugs
    • 3.2.3.2 Advancements in Dermatology Research and Technology
    • 3.2.3.3 Telemedicine and E-Health
• 3.3 COVID-19 Impact Analysis
• 3.4 Porter's Five Forces Analysis
  • 3.4.1 Bargaining Power of Suppliers
  • 3.4.2 Bargaining Power of Buyers
  • 3.4.3 Competitive Rivalry
  • 3.4.4 Threat from Substitutes
  • 3.4.5 Threat of New Entrants
• 3.5 PEST Analysis
  • 3.5.1 Political
  • 3.5.2 Economical
  • 3.5.3 Social
  • 3.5.4 Technological

4 Dermatological Drugs Market Analysis by Route of Administration

• 4.1 Key Findings
• 4.2 Route of Administration Segment: Market Attractiveness Index
• 4.3 Dermatological Drugs Market Size Estimation and Forecast by Route of Administration
• 4.4 Topical
  • 4.4.1 Market Size by Region, 2024-2034 (US$ Billion)
  • 4.4.2 Market Share by Region, 2024 & 2034 (%)
• 4.5 Oral
  • 4.5.1 Market Size by Region, 2024-2034 (US$ Billion)
  • 4.5.2 Market Share by Region, 2024 & 2034 (%)
• 4.6 Parenteral
  • 4.6.1 Market Size by Region, 2024-2034 (US$ Billion)
  • 4.6.2 Market Share by Region, 2024 & 2034 (%)

5 Dermatological Drugs Market Analysis by Disease

• 5.1 Key Findings
• 5.2 Disease Segment: Market Attractiveness Index
• 5.3 Dermatological Drugs Market Size Estimation and Forecast by Disease
• 5.4 Psoriasis
  • 5.4.1 Market Size by Region, 2024-2034 (US$ Billion)
  • 5.4.2 Market Share by Region, 2024 & 2034 (%)
• 5.5 Dermatitis
  • 5.5.1 Market Size by Region, 2024-2034 (US$ Billion)
  • 5.5.2 Market Share by Region, 2024 & 2034 (%)
• 5.6 Acne
  • 5.6.1 Market Size by Region, 2024-2034 (US$ Billion)
  • 5.6.2 Market Share by Region, 2024 & 2034 (%)
• 5.7 Skin Infections
  • 5.7.1 Market Size by Region, 2024-2034 (US$ Billion)
  • 5.7.2 Market Share by Region, 2024 & 2034 (%)
• 5.8 Others
  • 5.8.1 Market Size by Region, 2024-2034 (US$ Billion)
  • 5.8.2 Market Share by Region, 2024 & 2034 (%)

6 Dermatological Drugs Market Analysis by Prescription Mode

• 6.1 Key Findings
• 6.2 Prescription Mode Segment: Market Attractiveness Index
• 6.3 Dermatological Drugs Market Size Estimation and Forecast by Prescription Mode
• 6.4 Prescription Drugs
  • 6.4.1 Market Size by Region, 2024-2034 (US$ Billion)
  • 6.4.2 Market Share by Region, 2024 & 2034 (%)
• 6.5 Over-the-Counter (OTC) Drugs
  • 6.5.1 Market Size by Region, 2024-2034 (US$ Billion)
  • 6.5.2 Market Share by Region, 2024 & 2034 (%)

7 Dermatological Drugs market Analysis by Distribution Channel

• 7.1 Key Findings
• 7.2 Distribution Channel Segment: Market Attractiveness Index
• 7.3 Dermatological Drugs market Size Estimation and Forecast by Distribution Channel
• 7.4 Retail Pharmacies
  • 7.4.1 Market Size by Region, 2024-2034 (US$ Billion)
  • 7.4.2 Market Share by Region, 2024 & 2034 (%)
• 7.5 Hospital Pharmacies
  • 7.5.1 Market Size by Region, 2024-2034 (US$ Billion)
  • 7.5.2 Market Share by Region, 2024 & 2034 (%)
• 7.6 Online Pharmacies
  • 7.6.1 Market Size by Region, 2024-2034 (US$ Billion)
  • 7.6.2 Market Share by Region, 2024 & 2034 (%)
• 7.7 Others
  • 7.7.1 Market Size by Region, 2024-2034 (US$ Billion)
  • 7.7.2 Market Share by Region, 2024 & 2034 (%)

8 Dermatological Drugs Market Analysis by Region

• 8.1 Key Findings
• 8.2 Regional Market Size Estimation and Forecast

9 North America Dermatological Drugs Market Analysis

• 9.1 Key Findings
• 9.2 North America Dermatological Drugs Market Attractiveness Index
• 9.3 North America Dermatological Drugs market by Country, 2024, 2029 & 2034 (US$ Billion)
• 9.4 North America Dermatological Drugs Market Size Estimation and Forecast by Country
• 9.5 North America Dermatological Drugs Market Size Estimation and Forecast by Component
• 9.6 North America Dermatological Drugs Market Size Estimation and Forecast by Disease
• 9.7 North America Dermatological Drugs Market Size Estimation and Forecast by Prescription Mode
• 9.8 North America Dermatological Drugs Market Size Estimation and Forecast by Distribution Channel
• 9.9 U.S. Dermatological Drugs Market Analysis
• 9.10 Canada Dermatological Drugs Market Analysis

10 Europe Dermatological Drugs Market Analysis

• 10.1 Key Findings
• 10.2 Europe Dermatological Drugs Market Attractiveness Index
• 10.3 Europe Dermatological Drugs Market by Country, 2024, 2029 & 2034 (US$ Billion)
• 10.4 Europe Dermatological Drugs market Size Estimation and Forecast by Country
• 10.5 Europe Dermatological Drugs Market Size Estimation and Forecast by Route of Administration
• 10.6 Europe Dermatological Drugs Market Size Estimation and Forecast by Disease
• 10.7 Europe Dermatological Drugs Market Size Estimation and Forecast by Prescription Mode
• 10.8 Europe Dermatological Drugs Market Size Estimation and Forecast by Distribution Channel
• 10.9 Germany Dermatological Drugs Market Analysis
• 10.10 France Dermatological Drugs market Analysis
• 10.11 U.K. Dermatological Drugs market Analysis
• 10.12 Italy Dermatological Drugs market Analysis
• 10.13 Spain Dermatological Drugs Market Analysis
• 10.14 Rest of Europe Dermatological Drugs market Analysis

11 Asia Pacific Dermatological Drugs Market Analysis

• 11.1 Key Findings
• 11.2 Asia Pacific Dermatological Drugs Market Attractiveness Index
• 11.3 Asia Pacific Dermatological Drugs market by Country, 2024, 2029 & 2034 (US$ Billion)
• 11.4 Asia Pacific Dermatological Drugs Market Size Estimation and Forecast by Country
• 11.5 Asia Pacific Dermatological Drugs Market Size Estimation and Forecast by Component
• 11.6 Asia Pacific Dermatological Drugs Market Size Estimation and Forecast by Disease
• 11.7 Asia Pacific Dermatological Drugs Market Size Estimation and Forecast by Prescription Mode
• 11.8 Asia Pacific Dermatological Drugs Market Size Estimation and Forecast by Distribution Channel
• 11.9 China Dermatological Drugs Market Analysis
• 11.10 India Dermatological Drugs Market Analysis
• 11.11 Japan Dermatological Drugs Market Analysis
• 11.12 Australia Dermatological Drugs Market Analysis
• 11.13 South Korea Dermatological Drugs Market Analysis
• 11.14 Rest of Asia Pacific Dermatological Drugs market Analysis

12 Latin America Dermatological Drugs Market Analysis

• 12.1 Key Findings
• 12.2 Latin America Dermatological Drugs Market Attractiveness Index
• 12.3 Latin America Dermatological Drugs market by Country, 2024, 2029 & 2034 (US$ Billion)
• 12.4 Latin America Dermatological Drugs Market Size Estimation and Forecast by Country
• 12.5 Latin America Dermatological Drugs Market Size Estimation and Forecast by Component
• 12.6 Latin America Dermatological Drugs Market Size Estimation and Forecast by Disease
• 12.7 Latin America Dermatological Drugs Market Size Estimation and Forecast by Prescription Mode
• 12.8 Latin America Dermatological Drugs Market Size Estimation and Forecast by Distribution Channel
• 12.9 Brazil Dermatological Drugs Market Analysis
• 12.10 Mexico Dermatological Drugs market Analysis
• 12.11 Rest of Latin America Dermatological Drugs Market Analysis

13 MEA Dermatological Drugs market Analysis

• 13.1 Key Findings
• 13.2 MEA Dermatological Drugs Market Attractiveness Index
• 13.3 MEA Dermatological Drugs Market by Country, 2024, 2029 & 2034 (US$ Billion)
• 13.4 MEA Dermatological Drugs Market Size Estimation and Forecast by Country
• 13.5 MEA Dermatological Drugs Market Size Estimation and Forecast by Component
• 13.6 MEA Dermatological Drugs Market Size Estimation and Forecast by Disease
• 13.7 MEA Dermatological Drugs Market Size Estimation and Forecast by Prescription Mode
• 13.8 MEA Dermatological Drugs Market Size Estimation and Forecast by Distribution Channel
• 13.9 GCC Dermatological Drugs market Analysis
• 13.10 South Africa Dermatological Drugs market Analysis
• 13.11 Rest of MEA Dermatological Drugs market Analysis

14 Company Profiles

• 14.1 Competitive Landscape, 2023
• 14.2 Strategic Outlook
• 14.3 Novartis AG
  • 14.3.1 Company Snapshot
  • 14.3.2 Company Overview
  • 14.3.3 Financial Analysis
    • 14.3.3.1 Net Revenue, 2018-2022
    • 14.3.3.2 Regional Market Shares, 2022
    • 14.3.3.3 R&D Expense, 2018-2022
  • 14.3.4 Product Benchmarking
  • 14.3.5 Strategic Outlook
• 14.4 Bayer AG
  • 14.4.1 Company Snapshot
  • 14.4.2 Company Overview
  • 14.4.3 Financial Analysis
    • 14.4.3.1 Net Revenue, 2018-2022
    • 14.4.3.2 Regional Market Shares, 2022
    • 14.4.3.3 R&D Expense, 2018-2022
  • 14.4.4 Product Benchmarking
• 14.5 LEO Pharma A/S
  • 14.5.1 Company Snapshot
  • 14.5.2 Company Overview
  • 14.5.3 Product Benchmarking
  • 14.5.4 Strategic Outlook
• 14.6 Pfizer Inc.
  • 14.6.1 Company Snapshot
  • 14.6.2 Company Overview
  • 14.6.3 Financial Analysis
    • 14.6.3.1 Revenue, 2018-2022
    • 14.6.3.2 Regional Market Shares, 2022
    • 14.6.3.3 R&D Expense, 2018-2022
  • 14.6.4 Product Benchmarking
  • 14.6.5 Strategic Outlook
• 14.7 Johnson & Johnson Services, Inc.
  • 14.7.1 Company Snapshot
  • 14.7.2 Company Overview
  • 14.7.3 Financial Analysis
    • 14.7.3.1 Revenue, 2018-2022
    • 14.7.3.2 Regional Market Shares, 2022
    • 14.7.3.3 R&D Expense, 2018-2022
  • 14.7.4 Product Benchmarking
• 14.8 Regeneron Pharmaceuticals Inc.
  • 14.8.1 Company Snapshot
  • 14.8.2 Company Overview
  • 14.8.3 Financial Analysis
    • 14.8.3.1 Revenue, 2018-2022
    • 14.8.3.2 R&D Expense, 2018-2022
  • 14.8.4 Product Benchmarking
  • 14.8.5 Strategic Outlook
• 14.9 AbbVie Inc.
  • 14.9.1 Company Snapshot
  • 14.9.2 Company Overview
  • 14.9.3 Financial Analysis
    • 14.9.3.1 Revenue, 2018-2022
    • 14.9.3.2 Regional Market Shares, 2022
    • 14.9.3.3 R&D Expense, 2018-2022
  • 14.9.4 Product Benchmarking
  • 14.9.5 Strategic Outlook
• 14.10 Verrica Pharmaceuticals
  • 14.10.1 Company Snapshot
  • 14.10.2 Company Overview
  • 14.10.3 Product Benchmarking
• 14.11 Teva Pharmaceutical Industries Ltd.
  • 14.11.1 Company Snapshot
  • 14.11.2 Company Overview
  • 14.11.3 Financial Analysis
    • 14.11.3.1 Revenue, 2018-2022
    • 14.11.3.2 Regional Market Shares, 2022
    • 14.11.3.3 R&D Expense, 2018-2022
  • 14.11.4 Product Benchmarking
  • 14.11.5 Strategic Outlook
• 14.12 Roivant Sciences Ltd.
  • 14.12.1 Company Snapshot
  • 14.12.2 Company Overview
  • 14.12.3 Product Benchmarking
  • 14.12.4 Strategic Outlook
• 14.13 DermBiont, Inc.
  • 14.13.1 Company Snapshot
  • 14.13.2 Company Overview
  • 14.13.3 Product Benchmarking
  • 14.13.4 Strategic Outlook
• 14.14 AstraZeneca
  • 14.14.1 Company Snapshot
  • 14.14.2 Company Overview
  • 14.14.3 Financial Analysis
    • 14.14.3.1 Net Revenue, 2017-2022
    • 14.14.3.2 Regional Market Shares, 2022
    • 14.14.3.3 R&D Expense, 2018-2022
  • 14.14.4 Product Benchmarking
  • 14.14.5 Strategic Outlook
• 14.15 Merck & Co., Inc.
  • 14.15.1 Company Snapshot
  • 14.15.2 Company Overview
  • 14.15.3 Financial Analysis
    • 14.15.3.1 Net Revenue, 2017-2022
    • 14.15.3.2 Regional Market Shares, 2022
    • 14.15.3.3 R&D Expense, 2017-2022
  • 14.15.4 Product Benchmarking
• 14.16 GSK plc
  • 14.16.1 Company Snapshot
  • 14.16.2 Company Overview
  • 14.16.3 Financial Analysis
    • 14.16.3.1 Net Revenue, 2017-2022
    • 14.16.3.2 Regional Market Shares, 2022
    • 14.16.3.3 R&D Expense, 2017-2022
  • 14.16.4 Product Benchmarking
• 14.17 F. Hoffmann-La Roche Ltd
  • 14.17.1 Company Snapshot
  • 14.17.2 Company Overview
  • 14.17.3 Financial Analysis
    • 14.17.3.1 Net Revenue, 2018-2022
    • 14.17.3.2 R&D Expense, 2018-2022
  • 14.17.4 Product Benchmarking
• 14.18 Mayne Pharma Group Limited
  • 14.18.1 Company Snapshot
  • 14.18.2 Company Overview
  • 14.18.3 Financial Analysis
    • 14.18.3.1 Net Revenue, 2020-2023
    • 14.18.3.2 R&D Expense, 2020-2023
  • 14.18.4 Product Benchmarking
  • 14.18.5 Strategic Outlook

15 Conclusion and Recommendations

• 15.1 Concluding Remarks from Visiongain
• 15.2 Recommendations for Market Players